INmune Bio Inc. to Introduce NeuLiv™ Program for Treatment of NASH at H.C. Wainwright 21st Annual Global Investment Conference
INmune Bio Inc. - Common stock (INMB)
Company Research
Source: GlobeNewswire
NeuLiv™ is the Third Drug Development Program From Company’s DN-TNF Platform Presentation is Scheduled for 2.10 p.m. on Sept. 9th LA JOLLA, Calif., Sept. 04, 2019 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB), an immunotherapy company developing treatments that harness the patient’s innate immune system to fight disease, will introduce its NeuLiv™ development program for the treatment of nonalcoholic steatohepatitis (NASH) as part of a presentation at the H.C. Wainwright 21st Annual Global Investment Conference. Presentation Details: Location: The Lotte New York Palace Hotel, NY Date: Monday, September 9, 2019 at 2:10 p.m. ETPresentation Room: Louis, 4th Floor The presentation will be webcast live on September 9 and will remain available for 90 days through the Investor Relations section of INmune Bio’s website. “NASH presents a significant unmet medical need. We believe NeuLiv™ may enable us to target the underlying cause of NASH, to help stop the disease and allow t
Show less
Read more
Impact Snapshot
Event Time:
INMB
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
INMB alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
INMB alerts
High impacting INmune Bio Inc. - Common stock news events
Weekly update
A roundup of the hottest topics
INMB
News
- INmune Bio, Inc. (NASDAQ: INMB) had its price target raised by analysts at Maxim Group from $22.00 to $30.00. They now have a "buy" rating on the stock.MarketBeat
- INmune Bio price target raised to $23 from $22 at Scotiabank [Yahoo! Finance]Yahoo! Finance
- INmune Bio Opens Phase II in High Dose Cohort of INKmune™ Trial in Prostate CancerGlobeNewswire
- INmune Bio, Inc. (NASDAQ: INMB) had its price target raised by analysts at Scotiabank from $22.00 to $23.00. They now have a "sector outperform" rating on the stock.MarketBeat
- INmune Bio Announces Plan to Submit FDA Biologics License Application (BLA) Seeking Approval of CORDStrom for Treatment of Recessive Dystrophic Epidermolysis Bullosa (RDEB) [Yahoo! Finance]Yahoo! Finance
INMB
Earnings
- 10/31/24 - Miss
INMB
Sec Filings
- 2/12/25 - Form 8-K
- 2/10/25 - Form 8-K
- 2/10/25 - Form 8-K
- INMB's page on the SEC website